Phocas Financial Corp. Exelixis, Inc. Transaction History
Phocas Financial Corp.
- $749 Billion
- Q4 2024
A detailed history of Phocas Financial Corp. transactions in Exelixis, Inc. stock. As of the latest transaction made, Phocas Financial Corp. holds 109,093 shares of EXEL stock, worth $4.22 Million. This represents 0.49% of its overall portfolio holdings.
Number of Shares
109,093
Previous 16,574
558.22%
Holding current value
$4.22 Million
Previous $552 Million
558.25%
% of portfolio
0.49%
Previous 0.41%
Shares
10 transactions
Others Institutions Holding EXEL
# of Institutions
566Shares Held
251MCall Options Held
1.45MPut Options Held
1.13M-
Black Rock Inc. New York, NY33.5MShares$1.29 Billion0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA29.4MShares$1.14 Billion0.02% of portfolio
-
Farallon Capital Management LLC San Francisco, CA23.4MShares$906 Million4.16% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny15.3MShares$591 Million0.8% of portfolio
-
State Street Corp Boston, MA11.4MShares$441 Million0.02% of portfolio
About EXELIXIS, INC.
- Ticker EXEL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 321,832,000
- Market Cap $12.4B
- Description
- Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...